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Cannabinoids modulate inhibitory GABAergic neurotransmission in many brain regions. Within the temporal lobe, cannabinoid
receptors are highly expressed, and are located presynaptically at inhibitory terminals. Here, we have explored the role of
type-1 cannabinoid receptors (CB1Rs) at the level of inhibitory synaptic currents and field-recorded network oscillations. We
report that arachidonylcyclopropylamide (ACPA; 10 μM), an agonist at CB1R, inhibits GABAergic synaptic transmission onto
both superficial and deep medial entorhinal (mEC) neurones, but this has little eﬀect on network oscillations in beta/gamma
frequency bands. By contrast, the CB1R antagonist/inverse agonist LY320135 (500 nM), increased GABAergic synaptic activity and
beta/gamma oscillatory activity in superficial mEC, was suppressed, whilst that in deep mEC was enhanced. These data indicate
that cannabinoid-mediated eﬀects on inhibitory synaptic activity may be constitutively active in vitro, and that modulation of
CB1R activation using inverse agonists unmasks complex eﬀects of CBR function on network activity.
Copyright © 2008 Nicola H. Morgan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cannabinoid receptors are a family of G-protein coupled,
presynaptic receptors [1, 2]. Autoradiography studies using
the cannabinoid receptor ligand CP55,940 [3–5] show that
CB1Rs are distributed throughout neuronal tissue. These
studies report a dense binding of CP55,940 in the basal
ganglia, specifically the substantia nigra pars reticulata
the globus pallidus (GP) and also in cerebellum. In the
cerebrum, the hippocampal formation and the entorhinal
cortex (EC) show the highest density of staining for CB1R.
Cannabinoids are known to exert powerful control over
GABAergic inhibitory signalling in the CNS [6–8], and it is
reported that CB1R inhibition of GABAA receptor mediated
synaptic transmission occurs through the inhibition of
voltage-dependent calcium channels (VGCCs; [6]). In the
hippocampus, the activation of presynaptic CB1R depresses
GABA release onto postsynaptic target cells [9, 10], and
in these studies, endogenous and exogenous CB1R agonists
have been shown to reduce the amplitude and frequency
of GABAergic spontaneous inhibitory postsynaptic currents
(sIPSCs), but not to aﬀect action-potential-independent
miniature (m)IPSCs. Other studies have shown that cannabi-
noid receptor activation enhances network oscillatory activ-
ity [11]. However, in the parahippocampal region (PHR),
the eﬀects of cannabinoid receptors are less well described.
Here, we have investigated the functional eﬀects of CBRs on
neuronal network activity modelled in vitro by kainate (KA-)
induced persistent oscillations [8, 12]. Persistent oscillatory
activity in the gamma frequency band (30–80 Hz) has been
the most commonly reported and studied form of network
activity in the in vitro slice preparation, and can be elicited
by metabotropic glutamate receptors [13] or application of
kainic acid [8, 12] and/or the muscarinic agonist carbachol
Neuronal network oscillatory activity reflects the phasic
inhibition of principal cells by GABAergic interneurones,
which act to entrain and synchronize principal cell activity
(Cobb et al., [14]). The mEC has been reported to express
gamma oscillations (30–100 Hz) in response to application
2 Neural Plasticity
control
ACPA
LY320135
Po
w
er
(×
10
−9
μ
V
2
/H
z)
0
6
0 100
0 75
Frequency (Hz)
Frequency (Hz)
Po
w
er
(×
10
−9
μ
V
2
/H
z)
0
6
control
ACPA
LY320135
(b)
(c)(a)
Figure 1: The eﬀects of ACPA and LY320135 on γ-band activity in mEC layer II. (a) Example traces from layer II showing γ-oscillations
under conditions in which ACPA (10 μM) or LY320135 (500 nM) were applied. (b) Plot of power spectral density during drug application
(filtered between 2–100 Hz). Control (black line), ACPA (red line), LY320135 (blue line). (c) Similar plot to (b) bandpass filtered between
30–90 Hz. Scale bar = 200 milliseconds × 100 μV.
of nanomolar concentrations of kainate [15, 16], and oscil-
latory power was greatest in superficial layers II/III [15].
2. MATERIALS AND METHODS
Combined EC-hippocampal slices were prepared from
young male Wistar rats (50–110 g) as previously described
[17]. All experiments were performed in accordance with the
UK Animals (Scientific Procedures) Act 1986 and European
Communities Council Directive 1986 (86/609/EEC). Rats
were anaesthetised with isoflurane and N2/O2, until car-
diorespiratory arrest, and decapitated. The brain was rapidly
removed and immersed in oxygenated artificial cerebrospinal
fluid (ACSF) chilled to 4◦C. Slices (450 μm) were cut using
a vibrating microtome (MicroM, Germany), and stored in
ACSF continuously bubbled with 95% O2/5% CO2, at room
temperature. Following a recovery period of at least 1 hour,
individual slices were transferred to a recording chamber
mounted on the stage of an Olympus (BX50WI) upright
microscope. The chamber was continuously perfused with
oxygenated ACSF at 30–32◦C, at a flow rate of approximately
2 mL/min. The ACSF contained the following (in mM):
NaCl (126), KCl (3.25), NaH2PO4 (1.25), NaHCO3 (24),
MgSO4 (2), CaCl2 (2.5), and D-glucose (10). The solution
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Figure 2: The eﬀects of ACPA and LY320135 on β-band activity in mEC layer II. (a) Example traces from layer II showing β-oscillations
under conditions in which ACPA (10 μM) or LY320135 (500 nM) were applied. (b) Plot of power spectral density during drug application
(filtered between 2–100 Hz). Control (black line), ACPA (red line), LY320135 (blue line). (c) Similar plot to (b) bandpass filtered between
15–29 Hz. Scale bar = 200 milliseconds × 50 μV.
was continuously bubbled with 95% O2/5% CO2 to maintain
a pH of 7.4. Neurones were visualized using diﬀerential
interference contrast optics and an infrared video camera.
Patch-clamp electrodes were pulled from borosilicate
glass (1.2 mm OD, 0.69 ID; Harvard Apparatus) and had
open tip resistances of 4-5 MΩ. They were filled with a
solution containing the following (in mM): CsCl (90),
HEPES (33), QX-314 (5), EGTA (0.6), MgCl2 (5.0), TEA-Cl
(10), phosophocreatine (7) ATP (4), GTP (0.4). The solution
was adjusted to 290 mOsmol with sucrose and to pH 7.4
with CsOH. Whole-cell voltage clamp recordings were made
from neurones in layers II and V of the medial division of
the EC, using an Axopatch 700 series amplifier (Molecular
Devices, USA). The holding potential in all cases was –70 mV.
Under these experimental conditions, layer II/V neurones
exhibited sIPSCs, mediated by GABA acting primarily at
GABAA receptors.
Data were recorded directly to computer hard disk using
AxoScope software (Molecular Devices, USA). Mini Analysis
(Synaptosoft, USA) was used for analysis of sIPSCs oﬄine.
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Figure 3: The eﬀects of ACPA and LY320135 on γ-band activity in mEC layer V. (a) Example traces from layer V showing γ-oscillations
under conditions in which ACPA (10 μM) or LY320135 (500 nM) was applied. (b) Plot of power spectral density during drug application
(filtered between 2–100 Hz). Control (black line), ACPA (red line), or LY320135 (blue line). (c) Similar plot to (b) bandpass filtered between
30–90 Hz. Scale bar = 200 milliseconds × 50 μV.
sIPSCs were detected automatically using a threshold-
crossing algorithm, and their frequency and amplitude are
analysed. 200 sIPSCs were sampled during a continuous
recording period for each neurone under each condition. The
nonparametric Kolmogorov-Smirnoﬀ (KS) test was used to
assess the significance of shifts in cumulative probability
distributions of interevent interval (IEI). Diﬀerences between
drug and control situations in studies of sIPSCs were assessed
by means of a one-way ANOVA. All error values stated in the
text refer to the S.E.M.
All salts used in preparation of ACSF were Analar grade
and purchased from Merck/BDH (UK). LY320135 and ACPA
were obtained from Tocris Cookson (UK).
For field recordings of oscillatory activity, slices were
placed into an interface chamber (BRSC-1, Digitimer, UK)
and the chamber was continuously perfused with oxygenated
ACSF at 30–32◦C, at a flow rate of approximately 1-
2 mL/min. Extracellular population recordings were made
with glass microelectrodes filled with aCSF, of resistance
1–3 MΩ. Signals were amplified 1000-fold and recorded
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Figure 4: The eﬀects of ACPA and LY320135 on β-band activity in mEC layer V. (a) Example traces from layer V showing β-oscillations
under conditions in which ACPA (10 μM) or LY320135 (500 nM) were applied. (b) Plot of power spectral density during drug application
(filtered between 2–100 Hz). Control (black line), ACPA (red line), LY320135 (blue line). (c) Similar plot to (b) bandpass filtered between
15–29 Hz. Scale bar = 200 milliseconds × 50 μV.
unfiltered. Low amplitude 50 Hz interference was removed
using a HumBug (Quest Scientific, Canada). Signals were
digitized and recorded at 10 kHz using an NPI EXT-
02F amplifier (NPI, Germany) and pClamp 10 software
(Molecular Devices, USA). Following 30–90 minutes control
period of stable oscillatory activity, drugs were applied to the
bath in known concentration. Pharmacological oscillatory
activity was analysed using the fast Fourier transform (FFT,
Clampfit 10), cross-correlation analysis and Morlet-wavelet
time-frequency spectrogram analysis (MatLab 2007R, Math-
works). Student t-tests were carried out to determine
statistical significance.
We analysed oscillations at beta (15–29 Hz) and gamma
(30–90 Hz) bands, using bandpass filters (Clampfit 10.1) and
measurement of the area under the power spectrum curve in
Sigmaplot 8.0.
3. RESULTS
Whilst recording from layers II and V of the mEC, we applied
the CBR agonist arachidonylcyclopropylamide (ACPA) at
10 μM, onto slices from which stable gamma activity had
been induced by 300–400 nM kainate. As Figure 1(a) shows,
KA-induced gamma oscillations in layer II were broadly
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similar to those reported by Cunningham et al. [15]. Hence,
mean area power in the γ-band was 561 ± 179 μV2 and
mean control gamma frequency was 40.7±2.4 Hz. Following
40–60 minutes bath application of ACPA, we applied the
CB1R-specific inverse agonist LY320135 (500 nM; [18]).
Figure 1(b) shows the power spectral density of activity
bandpass filtered between 2–100 Hz, and Figure 1(c) shows
similar data filtered at gamma frequency (30–90 Hz). As
Figure 1(c) shows, there was a tendency towards an increase
in gamma power in ACPA in some recordings, but this
was not significant overall (P ≥ .19, n = 9). In pooled data,
ACPA did significantly reduce mean peak gamma frequency
to 35.6 ± 1.8 Hz (P ≤ .04, n = 9), although this eﬀect was
variable, and some recordings showed multiple peaks.
Following perfusion of the CB1R-specific inverse agonist
LY320135, there was a marked reduction in normalised
gamma power to 39.4 ± 10.1% of control, and this was
highly significant (P ≤ .0006, n = 9). In addition, mean peak
frequency returned to 41.2± 1.8 Hz (P ≤ .04, n = 9).
When beta power in layer II was measured, we noted
a similar pattern of drug responses to that observed for
gamma activity. Mean area power in the beta band was
lower than that of gamma activity at 26 ± 6 μV2 and mean
peak beta frequency in control conditions was 25.6 ±
1.4 Hz. Figure 2(a) shows the power spectral density of
activity bandpass filtered between 2–100 Hz, and Figure 2(c)
shows similar data filtered at beta frequency (15–29 Hz). As
Figure 2(c) shows, there was no significant change in beta
power in ACPA (81.4 ± 15% of control, P ≥ .14, n = 9), and
ACPA had no significant eﬀect on mean peak beta frequency
(27.6 ± 1.43 Hz, P ≥ .25, n = 9). However, when we added
the CB1R-specific inverse agonist LY320135, there was a
reduction in normalised beta power to 57 ± 13% of control,
and this was highly significant (P ≤ .008, n = 9). LY320135
had no eﬀect on mean peak frequency (27.9 ± 0.52 Hz,
P ≥ .4, n = 9).
During the above experiments, we simultaneously
recorded oscillatory activity in deep entorhinal cortex (layer
V). Oscillatory activity in layer V was lower in power in layer
V compared to layer II, with mean area gamma power just
60 ± 10 μV2 and mean peak frequency was similar to layer II
at 39.19± 3.1 Hz.
When we applied ACPA whilst recording in layer V
we observed a significant increase in mean gamma power
(Figure 3(a)), by 38.1 ± 13.4% of control (P ≤ .03, n = 9),
however, baseline gamma power was very low in this layer,
and the absolute change in gamma power was diﬃcult
to discern. Peak frequency was again slightly reduced to
36.0 ± 2.4 Hz, but this was not significant (P ≥ .31, n = 9).
On subsequent addition of the CB1R-specific inverse ago-
nist LY320135, there was a strong increase in normalised
gamma power to 108.4 ± 58% of control, and this reached
significance (P = .049, n = 9). Again, LY320135 did not
significantly alter mean peak gamma frequency (35.7 ±
2.41 Hz in LY320135, P ≥ .45, n = 9).
When beta power in layer V was analysed, we noted a
similar pattern of drug responses to that observed for gamma
activity. Mean area power in the beta band was lower than
that of gamma activity at 9.6 ± 0.6 μV2 and mean control
beta frequency was 27.9 ± 0.52 Hz. Figure 4(a) shows field
oscillations recorded in layer V before drug application and
during ACPA and LY320135 periods. Figure 4(b) shows the
power spectral density of activity bandpass filtered between
2–100 Hz, and Figure 4(c) shows similar data filtered at
beta frequency (15–29 Hz). As Figure 4(c) shows, there
was a slight tendency towards an increase in beta power
(by 27 ± 14%) in ACPA in some recordings, but this
was not significant overall (P ≥ .06, n = 9). ACPA had no
significant eﬀect on mean peak beta frequency (28.4 ±
0.7 Hz, P ≥ .5, n = 9). When we next applied the inverse
agonist LY320135, we noted an increase in normalised beta
power by 142.4 ± 88% of control, and this just failed to
reach significance (P ≤ .07, n = 9). LY320135 (26.3±1.5 Hz,
P ≥ .3, n = 9) had no eﬀect on peak frequency.
We hypothesised that the lack of eﬀects of ACPA in
layer II might reflect constitutive or tonic activation of
CBR, perhaps due to persistent kainate-induced activation
of pyramidal neurones. To test this hypothesis, we applied
LY320135 in the absence of ACPA. Application of LY320135
suppressed gamma band activity to 19.5 ± 11% of control,
and this was highly significant (P ≤ .01, n = 5). When beta
activity was measured, it was apparent that in LY320135,
there was a significant reduction in mean normalised beta
power (58.4 ± 12% of control; P ≤ .04, n = 5).
The data presented up to this point indicated that, in
general, gamma and beta power decreased in layer II in
response to blockade or inverse agonism of CB1R, and that
in layer V, the opposite was seen, with an increase in gamma
and beta power. Figures 5(a)-5(b) shows summary bar charts
indicating the eﬀects of ACPA and LY320135 on normalised
mean area power in the gamma and beta bands in layers II
and V of the mEC.
We hypothesised that the alterations in oscillatory power
seen during drug application would relate to the eﬀects of
ACPA and LY320135 on sIPSCs impinging on neurones in
deep and superficial entorhinal cortex. To measure these
eﬀects, we performed whole-cell voltage clamp recordings
of sIPSCs, whilst bath applying ACPA and LY320135 at
concentrations similar to those used above.
4. ACPA AND LY320135 HAVE SUBTLE
EFFECTS ON sIPSC AMPLITUDE AND
FREQUENCY IN mEC LAYER II
Figure 6(a) shows typical recordings of inward sIPSCs made
from a layer II pyramidal neurone. As Figure 6(b) shows, the
application of ACPA (10 μM) had subtle eﬀects on sIPSCs
in layer II, decreasing their frequency without aﬀecting
mean amplitude. Cumulative probability plots for sIPSC
amplitude in the presence of ACPA (Figure 6(c)) indicated
a shift in amplitude distribution, and mean amplitude
showed a slight increase from 101.7 ± 3.2 pA in control
to 108.3 ± 3.4 pA in ACPA, but this was nonsignificant
(P ≥ .168, ANOVA). When we analysed amplitude distribu-
tion using the nonparametric Kolmogorov-Smirnov test, the
shift towards higher amplitude sIPSCs was just significant
(P ≤ .021 KS test). In the case of interevent interval (IEI;
the reciprocal of frequency), we noted a shift to the right
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in the cumulative probability plot (Figure 6(d)), indicating
an increase in the likelihood of greater IEI values (reduced
frequency). Mean median IEI increased from 34.6 ± 5.5
milliseconds in control to 47.6 ± 9.7 milliseconds in ACPA
(P ≤ .0001, ANOVA, n = 5), and the increase in IEI time
distribution towards higher values was highly significant
(P ≤ .006, KS test). When we performed similar experiments
using LY320135 (500 nM), we noted eﬀects which tended
towards the opposite of those seen with ACPA, that is,
increased sIPSC amplitude and frequency. Figure 7(a) shows
a typical recording of inward sIPSCs made from a layer-II
pyramidal neurone. As Figure 7(b) shows, the application of
LY320135 increased sIPSC frequency and amplitude. Mean
amplitude increased from 51.7± 3.6 pA in control to 69.0±
5.9 pA in LY320135, and this was significant (P ≤ .013,
ANOVA, n = 6). Similarly, the shift in distribution towards
larger amplitudes was highly significant (P ≤ .002, KS test).
The mean median IEI showed a slight decrease from 86.6 ±
15.8 milliseconds in control to 80.6 ± 16.1 milliseconds
LY320135, but this decrease in IEI time was not significant
(P ≥ .116, ANOVA, n = 6).
The cumulative probability plots for sIPSC amplitude
(Figure 7(c)) and IEI (Figure 7(d)) in the presence of
LY320135 indicate the shifts in distribution of these parame-
ters in the presence of LY320135.
5. ACPA AND LY320135 HAVE MARKED
EFFECTS ON sIPSC AMPLITUDE AND
FREQUENCY IN mEC LAYER V
In contrast to the eﬀects observed in layer II and layer
V we noted a significant reduction in sIPSC frequency in
response to ACPA application. As Figure 8(a) shows, sIPSCs
in layer V are considerably less frequent than those in layer II
(see Woodhall et al., [17]). When ACPA was applied, sIPSC
frequency was greatly attenuated (Figure 8(b)), but there
was no overall shift in amplitude distribution (confirmed
by a nonsignificant KS test (P ≥ .23)). Mean amplitude
rose slightly from 59.41 ± 7.33 pA in control to 70.49 ±
8.89 pA in ACPA, but this increase was not significant
(P ≥ .33, ANOVA, n = 6). When we analysed IEI, the change
in distribution towards larger IEI values was significant
(P ≤ .0001 KS test), and mean median IEI was found to
increase very significantly from 792 ± 41 milliseconds in
control to 1317 ± 75 milliseconds in ACPA (P ≤ .0001,
ANOVA, n = 6). This eﬀect of ACPA on IEI in layer V was
consistent in all recordings. Cumulative probability plots
for sIPSC amplitude (Figure 8(c)) and IEI (Figure 8(d))
illustrate the eﬀects of ACPA on sIPSC amplitude and IEI.
When we performed similar experiments using
LY320135 (500 nM), we again noted robust eﬀects, which
opposed those seen with ACPA, that is, increased sIPSC
amplitude and frequency. Figure 9(a) shows a typical
recording of inward sIPSCs made from a layer-II pyramidal
neurone. As Figure 9(b) shows, the application of LY320135
had marked eﬀects on sIPSCs in layer V, increasing their
frequency and amplitude. Mean sIPSC amplitude in layer
V increased from 47.0 pA ± 3.0 to 87.9 pA ± 7.4 pA in
LY320135, and this increase was significant (P ≤ .001,
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Figure 5: Summary of the eﬀects of cannabinoid ligands on
oscillatory activity in mEC. (a) Bar charts showing the eﬀects of
cannabinoid ligands in layer II on normalised area power at γ and
β frequencies. (b) Bar charts showing the eﬀects of inverse agonists
alone in layer V on normalised area power at γ and β frequencies.
ANOVA n = 7). Cumulative probability plots for sIPSC
amplitude in the presence of LY320135 (Figure 9(c))
show the shift in amplitude distribution, and this was
confirmed statistically (P ≤ .0004, KS test). In the case
of IEI, we noted a shift to the left in the cumulative
probability plot (Figure 9(d)), indicating an increase in the
likelihood of lower IEI values (increased frequency). During
LY320135 application the mean median IEI decreased
from 477.1 ± 108.0 milliseconds in control to 300.0 ± 71.5
milliseconds in LY320135 showing that an overall increase in
sIPSC frequency has occurred. The decrease in mean median
IEI between control and LY320135 periods was significant
(P ≤ .014 ANOVA, n = 7), as was the change in distribution
(P ≤ .016, KS test).
6. DISCUSSION
We found that the cannabinoid receptor agonist ACPA had
little eﬀect on either oscillatory activity or synaptic inhibition
in superficial layers of the mEC, and that eﬀects in deep layers
were more robust, especially in the case of sIPSC frequency.
However, the inverse agonist, LY320135, strongly suppressed
oscillatory activity in superficial mEC even while its eﬀects
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Figure 6: The eﬀects of ACPA on sIPSCs in mEC layer II. (a) Recording from a layer II neurone under control conditions and (b) in the
presence of ACPA (10 μM). (c) Cumulative probability plot for sIPSC amplitude under control (black) and ACPA (red) conditions. (d)
Cumulative probability plot for sIPSC IEI under control (black) and ACPA (red) conditions. Scale bars 500 millisconds × 100 pA.
on sIPSC frequency and amplitude were not great. We also
observed that suppression of oscillatory activity in layer II by
LY3201235 was accompanied by augmentation of oscillatory
power in layer V, and that the suppression of sIPSCs by ACPA
and subsequent enhancement by LY320135 in this layer were
marked.
We have reported previously [17] that spontaneous
inhibition is much greater in superficial layer II of mEC than
in deep layer V. In addition, more than 90% of IPSCs in layer
II are action-potential (AP) independent, whereas in layer
V, AP-dependent events comprise a much greater (>50%)
proportion of sIPSCs. Given that CBRs act only on Ca2+
dependent release of GABA and have no eﬀect on mIPSCs
([8]; it seems likely that cannabinoid ligands would show
greater eﬀects in the deep layers, where activity is low at
baseline, and probably more sensitive to modulation since it
is more likely to be AP-dependent.
Since, compared to layer II, both ACPA and LY320135
had more profound eﬀects on synaptic inhibition in layer
V, it seems likely that the relative dominance of mIPSCs
in layer II may mask CB1R eﬀects on the minority of AP-
dependent sIPSCs to some degree. The lack of a robust eﬀect
of ACPA on oscillatory activity in layer V suggests, however,
that CB1R may already be activated by ongoing network
activity, and that further attempts at activation using an
agonist did not increase any eﬀect that CB1R might have on
oscillatory power. This appears to be supported by the eﬀects
of the inverse agonist LY320135 in layer II. Here, we observed
a robust reduction in both beta and gamma power in
layer II, suggesting that CB1R do contribute to maintaining
oscillatory activity in this layer. The apparently contradictory
result of enhanced oscillatory activity in layer V in response
to LY320125 may relate to eﬀects that are secondary to
activity in layer II, for example, Bragin [11], working in
vivo, noted that ablation of superficial EC causes augmented
oscillatory activity in CA3-CA1, and it may be that a similar
mechanism allows suppression of oscillations in layer II
to unmask activity in layer V, which receives inputs from
CA1. Similarly, previous reports [15] indicate that superficial
layers (especially layer III) show the strongest gamma power,
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Figure 7: The eﬀects of LY320135 on sIPSCs in mEC layer II. (a) Recording from a layer II neurone under control conditions and (b) in the
presence of LY320135 (500 nM). (c) Cumulative probability plot for sIPSC amplitude under control (black) and LY320135 (red) conditions.
(d) Cumulative probability plot for sIPSC IEI under control (black) and LY320135 (red) conditions. Scale bars 500 milliseconds × 250 pA.
perhaps suggesting a role in driving oscillatory activity in
other layers. However, layer V is not driven directly by layers
II or III [19], and hence any eﬀect in layer V may well be
indirect.
Cannabinoid receptors exert powerful control over
GABA release from presynaptic terminals, with CB1 recep-
tors having been shown to suppress both IPSPs and IPSCs in
pyramidal neurones (IPSPs, [20]; IPSCs, [8]). Endocannabi-
noids, such as 2-arachidonyl glycerol and anandamide
also suppress inhibition in CNS (see [21], for review).
Cannabinoids are also believed to mediate the phenomenon
of depolarisation-induced suppression of inhibition (DSI;
[22–24]). Recently, studies have suggested that CB1R are
present at terminals from specific subsets of inhibitory
interneurones. For example, fast spiking (FS) inhibitory
neurones in neocortex express parvalbumin (PV) but not
CB1R, and by contrast, irregular spiking (IS) neurones
express CB1R but not PV [25, 26]. Recently, Galaretta et al.
[27] have demonstrated that synapses between IS neurones
and pyramidal cells express CB1R and show DSI, whereas
synapses between FS neurones and pyramidal cells show
neither CB1R nor DSI. FS cells are thought to pace fast
oscillatory network rhythms such as gamma activity ([28];
and IS cells are thought to possess properties that predispose
towards nonrhythmic activity [25, 29]. A subset of neurones
that express CB1R but not PV expresses cholecystokinin
10 Neural Plasticity
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Figure 8: The eﬀects of ACPA on sIPSCs in mEC layer V. (a) Recording from a layer V neurone under control conditions and (b) in the
presence of ACPA (500 nM). (c) Cumulative probability plot for sIPSC amplitude under control (black) and ACPA (red) conditions. (d)
Cumulative probability plot for sIPSC IEI under control (black) and ACPA (red) conditions. Scale bars 2000 milliseconds × 250 pA.
(CCK), and these neurones have been suggested to act,
through DSI, to diﬀerentiate subgroups of pyramidal cells
into neuronal assemblies which are then entrained by FS
cells (“sparse coding” in place cell assemblies, [30]). In this
scenario, pyramidal cell activation leads to endocannabinoid
synthesis and release, which inhibits IS-cell inputs to the
somata and proximal dendrites of active cells, but allows
IS-cell-mediated inhibition to remain intact (and ongoing)
at less active pyramids. This eﬀect, in turn, allows FS-
cells to entrain oscillatory activity only at the disinhibited
population of pyramidal cells, eﬀectively selecting that subset
for rhythmic activity.
It seems possible that PV−/CCK+/CB1R+ inhibitory
interneurones might similarly select populations of pyra-
midal cells involved in rhythmogenesis in the mEC, which
contains both PV+ and PV− neurones [31, 32] and CCK+
interneurones [33], which also express CB1R [34]. We used
a selective cannabinoid receptor inverse agonist to globally
inhibit CB1Rs during persistent gamma and beta band
oscillations in brain slices from the mEC. Under conditions
in which CB1 were subject to blockade or inverse agonist
eﬀects, we observed a decrease in oscillatory power in
gamma and beta bands in layer II. This is consistent with
the literature described above [27, 30] and we propose
that, in layer II, blockade or inverse agonism of CBRs
results in increased irregular phasic inhibition from IS-cells
onto pyramidal cells, decreasing the population available
to participate in network oscillations and hence reducing
field oscillatory power. This appears to be supported by our
voltage-clamp recordings showing that LY320135 increased
phasic GABAergic inhibition at principal cells in layer II.
When we measured oscillatory activity in layer V, inverse
agonists at CBR increased gamma and beta power and this
appeared to be correlated with decreased superficial beta and
gamma power. At first, this appears paradoxical, however,
oscillatory activity in specific laminae does not exist in
isolation, and we might expect interactions between, as
well as within, networks of neurones. Bragin et al. [11]
have demonstrated that, in vivo, bilateral ablation of the
EC suppresses gamma activity in the dentate gyrus (DG),
but augments gamma oscillations in CA3-CA1. As previ-
ously discussed, superficial mEC projects to DG, and CA1
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Figure 9: The eﬀects of LY320135 on sIPSCs in mEC layer V. (a) Recording from a layer V neurone under control conditions and (b) in the
presence of LY320135 (500 nM). (c) Cumulative probability plot for sIPSC amplitude under control (black) and LY320135 (red) conditions.
(d) Cumulative probability plot for sIPSC IEI under control (black) and LY320135 (red) conditions. Scale bars 2000 milliseconds × 250 pA.
projects to deep mEC layers. Given that in our experiments,
oscillatory activity in superficial mEC was suppressed, it is
reasonable to suggest that this may depress gamma and/or
beta activity in DG and enhance such activity in CA3-CA1.
This, in turn, would feed through to layer V, where increased
gamma and beta power is seen. Hence, although phasic
inhibition in layer V appeared to increase in LY320135, it
may be that this eﬀect is not involved in selection of neuronal
assemblies for oscillatory activity in layer V; rather, excitatory
inputs to this area from hippocampus may be the dominant
influence on pyramidal cell activity.
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